1. Home
  2. AMSF vs ORKA Comparison

AMSF vs ORKA Comparison

Compare AMSF & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMSF
  • ORKA
  • Stock Information
  • Founded
  • AMSF 1985
  • ORKA 2004
  • Country
  • AMSF United States
  • ORKA United States
  • Employees
  • AMSF N/A
  • ORKA N/A
  • Industry
  • AMSF Accident &Health Insurance
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • AMSF Finance
  • ORKA Health Care
  • Exchange
  • AMSF Nasdaq
  • ORKA Nasdaq
  • Market Cap
  • AMSF 869.6M
  • ORKA 354.2M
  • IPO Year
  • AMSF 2005
  • ORKA N/A
  • Fundamental
  • Price
  • AMSF $43.53
  • ORKA $13.29
  • Analyst Decision
  • AMSF Buy
  • ORKA Strong Buy
  • Analyst Count
  • AMSF 2
  • ORKA 8
  • Target Price
  • AMSF $59.50
  • ORKA $39.71
  • AVG Volume (30 Days)
  • AMSF 151.7K
  • ORKA 337.9K
  • Earning Date
  • AMSF 07-24-2025
  • ORKA 08-15-2025
  • Dividend Yield
  • AMSF 10.52%
  • ORKA N/A
  • EPS Growth
  • AMSF N/A
  • ORKA N/A
  • EPS
  • AMSF 2.48
  • ORKA N/A
  • Revenue
  • AMSF $301,216,000.00
  • ORKA N/A
  • Revenue This Year
  • AMSF $1.69
  • ORKA N/A
  • Revenue Next Year
  • AMSF $6.54
  • ORKA N/A
  • P/E Ratio
  • AMSF $17.49
  • ORKA N/A
  • Revenue Growth
  • AMSF N/A
  • ORKA N/A
  • 52 Week Low
  • AMSF $42.48
  • ORKA $5.49
  • 52 Week High
  • AMSF $60.24
  • ORKA $52.32
  • Technical
  • Relative Strength Index (RSI)
  • AMSF 39.91
  • ORKA N/A
  • Support Level
  • AMSF $42.48
  • ORKA N/A
  • Resistance Level
  • AMSF $44.27
  • ORKA N/A
  • Average True Range (ATR)
  • AMSF 0.89
  • ORKA 0.00
  • MACD
  • AMSF 0.07
  • ORKA 0.00
  • Stochastic Oscillator
  • AMSF 42.68
  • ORKA 0.00

About AMSF AMERISAFE Inc.

AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: